AbbVie (NYSE:ABBV) Shares Up 2% – Time to Buy?

AbbVie Inc. (NYSE:ABBV)’s stock price rose 2% on Tuesday . The company traded as high as $219.17 and last traded at $217.3880. Approximately 8,170,519 shares were traded during trading, an increase of 11% from the average daily volume of 7,365,347 shares. The stock had previously closed at $213.12.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: BMO Capital maintained a Buy rating and $258 price target, reiterating confidence in AbbVie’s immunology strength and acquisition strategy — a visible analyst endorsement supporting investor demand. Article Title
• Positive Sentiment: Institutional buying: Beacon Investment Advisory increased its stake in AbbVie in Q4, signaling incremental shareholder support that can underpin the stock. Article Title
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) rolled out a consumer promotion (CoolMonth deals) and presented safety/efficacy data at AAD — actions that can boost aesthetics revenue and patient demand in the near term. Article Title
• Neutral Sentiment: AbbVie scheduled its Q1 2026 earnings release and conference call for April 29 — an upcoming catalyst that can drive volatility as investors reposition ahead of results and updated guidance. Article Title
• Neutral Sentiment: Broader obesity/peptide drug race coverage (PatentVest report on amylin programs) highlights shifting market dynamics in metabolic medicine that could reallocate R&D and M&A focus across pharma, including implications for AbbVie’s portfolio positioning. Article Title
• Negative Sentiment: Zacks flags near-term pressure in AbbVie’s oncology sales mix — Imbruvica pricing headwinds may weigh on top-line growth in 2026 despite contributions from newer oncology drugs. Article Title
• Negative Sentiment: Competitive pressure in dermatology: J&J’s launch of Icotyde raises rivalry for AbbVie’s Skyrizi, though AbbVie publicly asserts Skyrizi’s efficacy edge — competition could compress market share/pricing over time. Article Title

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Morgan Stanley lifted their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Royal Bank Of Canada initiated coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Trading Up 2.0%

The company has a market capitalization of $384.38 billion, a price-to-earnings ratio of 92.11, a PEG ratio of 0.73 and a beta of 0.34. The firm’s 50-day moving average price is $221.93 and its 200 day moving average price is $224.66.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the company posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. AbbVie’s dividend payout ratio is 293.22%.

Insiders Place Their Bets

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

Hedge Funds Weigh In On AbbVie

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Diversified Trust Co raised its holdings in shares of AbbVie by 23.6% during the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after purchasing an additional 10,891 shares during the period. Permanent Capital Management LP acquired a new stake in shares of AbbVie in the 3rd quarter valued at about $720,000. Railway Pension Investments Ltd increased its position in AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after buying an additional 211,800 shares in the last quarter. World Investment Advisors increased its position in AbbVie by 9.4% in the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company’s stock valued at $26,378,000 after buying an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co raised its stake in AbbVie by 93.4% during the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after buying an additional 15,502 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.